Superworth60 Degrees Pharmaceuticals SXTP
- Market cap
- $3.1M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.8×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $1.1M
- +73% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −290.7%
60 Degrees Pharmaceuticals trades at 2.8× sales. Revenue was $1.1M over the last twelve months, up 73% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $51.2K−70% | $125.7K | $105.7K+515% | $125K+110% | $135.3K+164% | $241.6K+92% | $163.6K+55% | $100.9K−19% | $437.6K+223% | $303.4K+26% | $162.1K−1% | $207.9K+106% | |
| Cost of revenue | $71.2K−23% | $146.3K | $65.4K−11% | $89.6K−51% | $111.7K+57% | $118.1K−19% | $73.3K+12% | $50.1K−44% | $537.7K+381% | $120.7K+2% | $85.7K+17% | $151.1K+202% |
| Gross profit | −$20K | −$20.6K | $40.2K | $35.4K | $23.6K | $123.6K | $90.3K+124% | $50.9K+44% | −$100.1K | $182.7K+48% | $76.4K−15% | $56.8K+12% |
| R&D | $263.7K+854% | $100.2K | $337.2K+172% | $3.1M+1418% | $940.1K+257% | $614K+513% | $370.8K+10% | $231.9K−93% | $809.8K−14% | $638.9K+4% | $281.5K−24% | $598.7K+158% |
| SG&A | $1.3M+218% | $1.7M | $1.1M+39% | $1.1M+144% | $1.2M−8% | $1.6M−5% | $1.7M+60% | $1.6M+45% | $1.5M+24% | $1.5M−8% | $1.9M+10% | $1.7M+6% |
| −$1.5M+607% | −$1.9M | −$1.3M+41% | −$4.2M+432% | −$2.1M+39% | −$2.1M+9% | −$1.9M+42% | −$1.6M−62% | −$2.3M+10% | −$1.9M−7% | −$2.1M+10% | −$2.3M+41% | |
| Interest expense | $4.9K−100% | $2.2M | $1.4K−100% | $3.6K−100% | $1.5K−70% | $1.4K−100% | $1.8K+28% | $1.2K−66% | $1.7K+16% | $3.1K+117% | $1.4K−22% | $1.4K+15% |
| Pre-tax income | $4.2M | −$2M | $428K | −$4.2M+25% | −$2.2M | −$2M+0% | −$1.9M | −$1.7M−58% | −$2.3M+7% | −$1.4M−30% | −$2.1M+11% | −$2.3M+31% |
| $63−75% | $61 | $63+0% | $438+595% | $250+297% | −$751 | $63+0% | $1.5K+243% | $250+0% | −$1.8K+141% | n/a | n/a | |
| Net income | $4.2M | −$2M+20% | $430.5K | −$4.2M+25% | −$2.2M | −$2M+2% | −$1.9M | −$1.7M−59% | −$2.3M+7% | −$1.4M−30% | −$2.1M+11% | −$2.3M+31% |
| $182.60 | −$86.40−48% | $7.32 | −$84.48−75% | −$11.68 | −$9.16−89% | −$6.25 | −$5.01−94% | −$2.64−77% | n/a | −$1.28−80% | −$0.90−82% | |
| 22.4K+125% | 24.1K+143% | 42.2K+339% | 50.7K+412% | 538.2K+2302% | 238.1K+888% | 320.9K+661% | 368.3K+626% | 918.9K+71% | n/a | 1.7M+438% | 2.7M+621% |
Revenue: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them. 4 periods, Q2 FY22 to Q3 FY23: not printed by the filing, worked out from its own lines.
R&D: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
SG&A: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Operating income: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Income tax: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Net income: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY22 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY22: share-days: the 6-month average less the second quarter's. Q4 FY22 and Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x4).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest 60 Degrees Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SXTP60 Degrees Pharmaceuticals | $3.1M | n/m | n/a | 2.8× | +73% | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| CKXCKX Lands | $21.5M | 7.4× | 32.6× | 31.0× | −17% | n/m | |
| MSGMMotorsport Games | $22.5M | 11.4× | 11.5× | 1.5× | +79% | 16.2% | |
| ATCHAtlasClear | $24M | 15.8× | 17.5× | 1.2× | +85% | 9.8% | |
| Peer median | $18.9M | 9.4× | 13.4× | 1.4× | −3% | 8.6% |
More on 60 Degrees Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .